AKTS
Aktis Oncology, Inc.
Price Chart
Latest Quote
$21.98
Current Price| Previous Close | $20.25 |
| Open | $20.24 |
| Day High | $21.99 |
| Day Low | $19.90 |
| Volume | 162,985 |
Stock Information
| Shares Outstanding | 50.65M |
| Total Debt | $12.01M |
| Cash Equivalents | $297.17M |
| Revenue | $5.56M |
| Net Income | $-60.65M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.15B |
| EPS (TTM) | $-1.16 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 20/42| Debt to Equity | -0.14 |
| Debt to Earnings | -0.27 |
| Current Ratio | 15.98 |
| Quick Ratio | 15.79 |
| Profit Margin | -2957.63% |
| Return on Equity | 50.09% |
| Avg FCF Growth | -52.75% |
| FCF Yield | 1.03% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $21.98 | 163,600 |
| 2026-01-30 | $20.25 | 162,700 |
| 2026-01-29 | $19.64 | 375,600 |
| 2026-01-28 | $20.50 | 171,600 |
| 2026-01-27 | $21.22 | 355,400 |
| 2026-01-26 | $21.62 | 237,100 |
| 2026-01-23 | $21.65 | 232,900 |
| 2026-01-22 | $22.40 | 432,600 |
| 2026-01-21 | $20.40 | 310,700 |
| 2026-01-20 | $18.77 | 270,800 |
| 2026-01-16 | $19.75 | 319,200 |
| 2026-01-15 | $20.56 | 235,100 |
| 2026-01-14 | $20.81 | 569,700 |
| 2026-01-13 | $21.35 | 292,100 |
| 2026-01-12 | $21.75 | 829,700 |
| 2026-01-09 | $22.40 | 3,117,000 |
About Aktis Oncology, Inc.
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD276 expressing tumors targeting prostate, lung and other solid tumors. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is based in Boston, Massachusetts.
📰 Latest News
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs
24/7 Wall St. • 2026-01-19T13:45:46Z
Assessing Aktis Oncology (AKTS) Valuation After IPO, NASDAQ Inclusion And Heavy Insider And Institutional Buying
Simply Wall St. • 2026-01-18T20:08:48Z
MarketBeat Week in Review – 01/12 - 01/16
MarketBeat • 2026-01-17T12:00:00ZA Fresh IPO That Long-Term Investors Shouldn’t Ignore
MarketBeat • 2026-01-14T14:31:00Z
Aktis Oncology Jumps 27% After $318 Million Upsized IPO
GuruFocus.com • 2026-01-09T18:24:59Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Revenue | $1,487,000 | $0 | $0 |
| Operating Revenue | $1,487,000 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Expenses | $53,537,000 | $34,794,000 | $19,764,000 |
| Other Income Expense | $-33,000 | $776,000 | $188,000 |
| Other Non Operating Income Expenses | $-25,000 | $-24,000 | $-12,000 |
| Net Non Operating Interest Income Expense | $8,103,000 | $5,377,000 | $1,647,000 |
| Operating Expense | $53,537,000 | $34,794,000 | $19,764,000 |
| General And Administrative Expense | $11,307,000 | $7,679,000 | $5,106,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-43,980,000 | $-28,641,000 | $-17,929,000 |
| Net Interest Income | $8,103,000 | $5,377,000 | $1,647,000 |
| Interest Income | $8,103,000 | $5,377,000 | $1,647,000 |
| Normalized Income | $-43,972,000 | $-29,441,000 | $-18,129,000 |
| Net Income From Continuing And Discontinued Operation | $-43,980,000 | $-28,641,000 | $-17,929,000 |
| Total Operating Income As Reported | $-52,050,000 | $-34,794,000 | $-19,764,000 |
| Net Income Common Stockholders | $-43,980,000 | $-28,641,000 | $-17,929,000 |
| Net Income | $-43,980,000 | $-28,641,000 | $-17,929,000 |
| Net Income Including Noncontrolling Interests | $-43,980,000 | $-28,641,000 | $-17,929,000 |
| Net Income Continuous Operations | $-43,980,000 | $-28,641,000 | $-17,929,000 |
| Pretax Income | $-43,980,000 | $-28,641,000 | $-17,929,000 |
| Interest Income Non Operating | $8,103,000 | $5,377,000 | $1,647,000 |
| Operating Income | $-52,050,000 | $-34,794,000 | $-19,764,000 |
| Depreciation Amortization Depletion Income Statement | $1,276,000 | $1,196,000 | $356,000 |
| Depreciation And Amortization In Income Statement | $1,276,000 | $1,196,000 | $356,000 |
| Depreciation Income Statement | $1,276,000 | $1,196,000 | $356,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-50,467,000 | $-34,398,000 | $-19,519,000 |
| Total Unusual Items | $-8,000 | $800,000 | $200,000 |
| Total Unusual Items Excluding Goodwill | $-8,000 | $800,000 | $200,000 |
| Reconciled Depreciation | $1,575,000 | $1,120,000 | $445,000 |
| EBITDA (Bullshit earnings) | $-50,475,000 | $-33,598,000 | $-19,319,000 |
| EBIT | $-52,050,000 | $-34,794,000 | $-19,764,000 |
| Diluted NI Availto Com Stockholders | $-43,980,000 | $-28,641,000 | $-17,929,000 |
| Gain On Sale Of Security | $-8,000 | $800,000 | $200,000 |
| Research And Development | $40,954,000 | $25,919,000 | $14,302,000 |
| Selling General And Administration | $11,307,000 | $7,679,000 | $5,106,000 |
| Other Gand A | $5,164,000 | $2,917,000 | $2,177,000 |
| Salaries And Wages | $6,143,000 | $4,762,000 | $2,929,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Net Tangible Assets | $-87,803,000 | $-46,306,000 | $-19,230,000 |
| Total Assets | $326,181,000 | $122,355,000 | $138,322,000 |
| Total Non Current Assets | $25,328,000 | $22,151,000 | $5,841,000 |
| Other Non Current Assets | $4,457,000 | $1,227,000 | $976,000 |
| Current Assets | $300,853,000 | $100,204,000 | $132,481,000 |
| Other Current Assets | $3,685,000 | $2,342,000 | $3,884,000 |
| Cash Cash Equivalents And Short Term Investments | $297,168,000 | $97,862,000 | $128,597,000 |
| Cash And Cash Equivalents | $37,159,000 | $29,513,000 | $128,597,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Debt | $12,010,000 | $13,402,000 | $1,775,000 |
| Long Term Debt And Capital Lease Obligation | $10,714,000 | $11,874,000 | $921,000 |
| Current Debt And Capital Lease Obligation | $1,296,000 | $1,528,000 | $854,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Liabilities Net Minority Interest | $413,984,000 | $168,661,000 | $157,552,000 |
| Total Non Current Liabilities Net Minority Interest | $395,162,000 | $162,424,000 | $152,277,000 |
| Non Current Deferred Liabilities | $51,039,000 | $0 | - |
| Current Liabilities | $18,822,000 | $6,237,000 | $5,275,000 |
| Current Deferred Liabilities | $9,277,000 | $0 | - |
| Payables And Accrued Expenses | $5,165,000 | $2,676,000 | $3,227,000 |
| Payables | $1,918,000 | $957,000 | $490,000 |
| Accounts Payable | $1,918,000 | $957,000 | $490,000 |
| Other Non Current Liabilities | - | - | $6,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Common Stock Equity | $-87,803,000 | $-46,306,000 | $-19,230,000 |
| Total Equity Gross Minority Interest | $-87,803,000 | $-46,306,000 | $-19,230,000 |
| Stockholders Equity | $-87,803,000 | $-46,306,000 | $-19,230,000 |
| Gains Losses Not Affecting Retained Earnings | $124,000 | $82,000 | $0 |
| Other Equity Adjustments | $124,000 | $82,000 | - |
| Retained Earnings | $-92,833,000 | $-48,853,000 | $-20,212,000 |
| Preferred Securities Outside Stock Equity | $333,409,000 | $150,550,000 | $151,350,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Tangible Book Value | $-87,803,000 | $-46,306,000 | $-19,230,000 |
| Invested Capital | $-87,803,000 | $-46,306,000 | $-19,230,000 |
| Working Capital | $282,031,000 | $93,967,000 | $127,206,000 |
| Capital Lease Obligations | $12,010,000 | $13,402,000 | $1,775,000 |
| Total Capitalization | $-87,803,000 | $-46,306,000 | $-19,230,000 |
| Additional Paid In Capital | $4,906,000 | $2,465,000 | $982,000 |
| Capital Stock | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 |
| Non Current Deferred Revenue | $51,039,000 | $0 | - |
| Long Term Capital Lease Obligation | $10,714,000 | $11,874,000 | $921,000 |
| Current Deferred Revenue | $9,277,000 | $0 | - |
| Current Capital Lease Obligation | $1,296,000 | $1,528,000 | $854,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,084,000 | $2,033,000 | $1,194,000 |
| Current Accrued Expenses | $3,247,000 | $1,719,000 | $2,737,000 |
| Net PPE | $20,871,000 | $20,924,000 | $4,865,000 |
| Accumulated Depreciation | $-3,229,000 | $-1,653,000 | $-533,000 |
| Gross PPE | $24,100,000 | $22,577,000 | $5,398,000 |
| Leases | $167,000 | $167,000 | $167,000 |
| Construction In Progress | $1,332,000 | $395,000 | $557,000 |
| Other Properties | $21,847,000 | $21,289,000 | $4,403,000 |
| Machinery Furniture Equipment | $754,000 | $726,000 | $271,000 |
| Properties | $0 | $0 | $0 |
| Other Short Term Investments | $260,009,000 | $68,349,000 | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Free Cash Flow | $11,900,000 | $-33,768,000 | $-20,432,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Operating Cash Flow | $14,762,000 | $-30,004,000 | $-18,125,000 |
| Cash Flow From Continuing Operating Activities | $14,762,000 | $-30,004,000 | $-18,125,000 |
| Operating Gains Losses | $8,000 | $-800,000 | $-200,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Capital Expenditure | $-2,862,000 | $-3,764,000 | $-2,307,000 |
| Investing Cash Flow | $-190,400,000 | $-68,828,000 | $-2,307,000 |
| Cash Flow From Continuing Investing Activities | $-190,400,000 | $-68,828,000 | $-2,307,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Issuance Of Capital Stock | $185,000,000 | $0 | $120,135,000 |
| Financing Cash Flow | $183,284,000 | $0 | $119,984,000 |
| Cash Flow From Continuing Financing Activities | $183,284,000 | $0 | $119,984,000 |
| Net Other Financing Charges | $-1,895,000 | - | $-151,000 |
| Net Preferred Stock Issuance | $185,000,000 | $0 | $120,135,000 |
| Preferred Stock Issuance | $185,000,000 | $0 | $120,135,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| End Cash Position | $38,308,000 | $30,662,000 | $129,494,000 |
| Beginning Cash Position | $30,662,000 | $129,494,000 | $29,942,000 |
| Changes In Cash | $7,646,000 | $-98,832,000 | $99,552,000 |
| Proceeds From Stock Option Exercised | $179,000 | $0 | - |
| Net Investment Purchase And Sale | $-187,538,000 | $-65,121,000 | $0 |
| Sale Of Investment | $100,858,000 | $80,685,000 | $0 |
| Purchase Of Investment | $-288,396,000 | $-145,806,000 | $0 |
| Net PPE Purchase And Sale | $-2,862,000 | $-3,707,000 | $-2,307,000 |
| Sale Of PPE | $0 | $57,000 | $0 |
| Purchase Of PPE | $-2,862,000 | $-3,764,000 | $-2,307,000 |
| Change In Working Capital | $58,980,000 | $-15,000 | $-1,139,000 |
| Change In Other Working Capital | $58,513,000 | - | - |
| Change In Other Current Liabilities | $-1,522,000 | $-2,284,000 | $-566,000 |
| Change In Other Current Assets | $820,000 | $1,829,000 | $507,000 |
| Change In Payables And Accrued Expense | $2,512,000 | $432,000 | $2,536,000 |
| Change In Accrued Expense | $2,152,000 | $-227,000 | $2,537,000 |
| Change In Payable | $360,000 | $659,000 | $-1,000 |
| Change In Account Payable | $360,000 | $659,000 | $-1,000 |
| Change In Prepaid Assets | $-482,000 | $265,000 | $-3,616,000 |
| Change In Receivables | $-861,000 | $-257,000 | $0 |
| Stock Based Compensation | $2,260,000 | $1,478,000 | $698,000 |
| Amortization Of Securities | $-4,081,000 | $-3,146,000 | $0 |
| Depreciation Amortization Depletion | $1,575,000 | $1,120,000 | $445,000 |
| Depreciation And Amortization | $1,575,000 | $1,120,000 | $445,000 |
| Gain Loss On Investment Securities | $8,000 | $-800,000 | $-200,000 |
| Net Income From Continuing Operations | $-43,980,000 | $-28,641,000 | $-17,929,000 |